BioWorld

Feb. 13, 2009

Portola's Anticlotting Drug Gains Partner in Potential $575M Deal

In its first major collaboration, privately held Portola Pharmaceuticals Inc. partnered one of its two lead antithrombotic programs with Novartis AG in a deal potentially worth up to $575 million. (BioWorld Today) Read More

Futility Analysis Derails BioMarin and LJP's Phase III Riquent Trial

Better Blood Supply Leads to Better-Behaved Tumors

Insmed Jumps on Merck $130M Bid for FOBs Drugs

Holiday Notice

Corrections & Clarifications

Alios Closes $8.4M Tranche of $24M Series A Round

Oscient and Telik Cut Deep to Conserve Capital

Novelos, Mundipharma Sign $95M Deal for Cancer Drug

Appointments And Advancements

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...